Tal Gavoli

Every person will get exactly what's relevant just for them.

Okay, sure.

So first, you tell us only what you know.

Okay, that's one thing.

So we ask a bunch of questions, and if you know the answer is great.

If you don't, just say, I don't know, and skip it.

So tell us as much as you can.

And most people know what meds they're taking, what the doctor told them.

Do they have type 1 or type 2?

What's A1C level in their last result?

They know information about themselves or what type of breast cancer they had and so on.

So they know enough to give us a direction.

That's one.

So they first—

provide that information.

By the way, the more information they provide, the more personalized it is.

And how we make money, so on one hand, we license the technology and content to various partners like the Leukemia and Lymphoma Society, like healthcare providers.

And on the other hand, we are paid by biopharma to reach and engage hard-to-find patients without compromising the privacy or the security of the patient.

So the patient is always in the driver's seat.

They always are the ones that make the choices.